Dare Bioscience (DARE) Other Non-Current Assets (2013 - 2026)
Dare Bioscience's (DARE) quarterly Other Non-Current Assets came in at $1.0 million in Q4 2025, down 9.11% YoY from $1.1 million in Q4 2024, and down 0.88% on a QoQ basis from $1.0 million in Q3 2025.
Dare Bioscience (DARE) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Other Non-Current Assets data on file, last reported at $1.0 million in Q4 2025.
- Quarterly Other Non-Current Assets fell 9.11% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (down 9.11% YoY) and the FY2025 annual result came in at $1.0 million, down 9.11% from the prior year.
- Other Non-Current Assets fell to $1.0 million in Q4 2025, from $1.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.8 million in Q3 2023 to a low of $10502.0 in Q4 2022.
- A 5-year average of $888394.1 and a median of $904369.0 in 2021 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets sank 97.84% — and 2023, when it surged 10978.62%.
- Tracing DARE's Other Non-Current Assets over 5 years: stood at $485120.0 in 2021, then slumped by 97.84% to $10502.0 in 2022, then surged by 10978.62% to $1.2 million in 2023, then slipped by 4.55% to $1.1 million in 2024, then decreased by 9.11% to $1.0 million in 2025.
- The last three Other Non-Current Assets figures came in at $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | 2.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.55 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 544,499.00 |
| Jun 30, 2024 | 528,571.00 |
| Mar 31, 2024 | 762,432.00 |
| Dec 31, 2023 | 1.16 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 920,880.00 |
| Mar 31, 2023 | 799,327.00 |
| Dec 31, 2022 | 10,502.00 |
| Sep 30, 2022 | 736,514.00 |
| Jun 30, 2022 | 1.26 Mn |
| Mar 31, 2022 | 1.34 Mn |
| Dec 31, 2021 | 485,120.00 |
| Sep 30, 2021 | 535,234.00 |
| Jun 30, 2021 | 738,283.00 |